CDx-associated SV, CNA, and RE were concordant across intra-tumoural space, consistent with early emergence (a.k.a. truncal mutation) and stability during tumorigenesis. Overall, these results have important implications for diagnostic testing, including patient biopsy/surgical sampling and laboratory microdissection practices, which we find to be sound for the detection of therapy-related AGA in this study.

5 months ago

Clinical

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog)

BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • EGFR L858R • PTEN mutation • ALK fusion • RAS wild-type • EGFR mutation + PTEN mutation • MET D1010H

FoundationOne® CDx

over2years

Characterization of MET exon 14 skipping in pancancer. (ASCO 2022)

Here we reported diverse METex14 alterations in a Chinese pan-cancer cohort that contribute to oncogenic transformation. METex14 mutations of pan-cancer mainly occurred in SD site. TP53 was its main co-mutant gene among pan-cancers, and MET amplification was also observed.

over 2 years ago

Pan tumor

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)

TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET exon 14 mutation • EML4-ALK fusion • ALK fusion • CDK4 amplification • MET fusion • MET D1010H